Communiqués Sprint Bioscience AB

Actions

SPRINT

SE0006343745

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq Stockholm Autres places de cotation 18:00:00 06/07/2026			Varia. 5j.	Varia. 1 janv.
3,700 ^SEK	-9,09%		-13,95%	+151,70%

26/06	Quatre actions atteignent un nouveau sommet annuel sur la Bourse de Stockholm	FW
18/06	Bourse de Stockholm : neuf actions inscrivent un nouveau plus haut sur 52 semaines ce jour	FW

Communiqués

04/06	Sprint Bioscience (publ) announces that Aktiespararna initiates commissioned research coverage of the company	AQ
19/05	Sprint Bioscience (Q1 Review): Momentum in the business	AQ
16/04	Sprint Bioscience completes strategic STK25 evaluation; continued focus on the primary indication	AQ
01/04	Sprint Bioscience appoints Jenni Björnulfson as CFO	AQ
01/04	Positive results expand the NNMT program into Chronic Kidney Disease	AQ
27/03	Sprint Bioscience publishes new research findings that strengthen the potential of DCPS inhibitors in AML	AQ
18/03	Sprint Bioscience presents new preclinical data on DCPS at the AACR Annual Meeting 2026	AQ
17/03	Sprint Bioscience reports positive results from the VRK1 program	AQ
13/02	Sprint Bioscience (Q4 Review): Promising development	AQ
05/12	Sprint Bioscience (Q3 review) - Gilead deal a strong confirmation	AQ
27/11	Sprint Bioscience: ”We have shown it's possible to make early deals”	AQ
24/11	Sprint Bioscience sells the TREX1 program to Gilead	AQ
04/09/25	Sprint Bioscience - A clear objective to secure a new partner	AQ
26/06/25	Sprint Bioscience’s DCPS data published in Leukemia	AQ
18/06/25	Sprint Bioscience collaborates to expand its MASH programme into inflammation	AQ
30/05/25	Sprint Bioscience - Increased pressure ahead of the next sprint baton-exchange	AQ
04/03/25	Sprint Bioscience presents the VPS34 program at two scientific conferences	AQ
17/02/25	Sprint Bioscience presents preclinical data from the TREX1 program at AACR IO	AQ
13/02/25	Sprint Bioscience Q4 - Confident expansion	AQ
08/01/25	Sprint Biosciences upcoming activities	AQ
18/12/24	Sprint Bioscience adds new cancer drug program to portfolio	AQ
04/11/24	Sprint Bioscience will present at the BioStock Life Science Summit, November 21	AQ
31/10/24	Sprint Bioscience Q3 - Steady sales and continued progress	AQ
09/10/24	BioStock: Sprint Bioscience CEO comments on deal potential	AQ
30/08/24	Sprint Bioscience Update - Robust sales and project activity	AQ